Current opinion in organ transplantation · 2026
Precision medicine guided development of new immunosuppression strategies in solid organ transplantation.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pai Priya K, Emamaullee Juliet, Eiamkulbutr Sutha
Аннотация
PURPOSE OF REVIEW: Corticosteroids, calcineurin inhibitors, antimetabolites, and mammalian target of rapamycin (mTOR) inhibitors have formed the basis of immunosuppression in clinical solid organ transplantation for decades. This review aims to outline recent advances in precision-based immunosuppression for solid organ transplantation.
RECENT FINDINGS: Co-stimulation blockade has been explored as both tolerogenic and maintenance immunosuppression over the last two decades, resulting in the application of belatacept in clinical settings. Dual co-stimulation blockade is the latest in this area of study. Recent updates in monoclonal antibody-based immunotherapy have resulted in widespread off-label clinical implementation of eculizumab and alemtuzumab with new drugs still in phase II/II trials. Additional strategies, including autologous regulatory T cell (Treg) and chimeric antigen receptor-Treg cell (CAR-Treg) based therapies, are at the forefront of therapeutic immunomodulation. Early data have demonstrated safety and feasibility with ongoing phase II studies in these cell-based therapies, aiming to verify efficacy in early and long-term graft survival.
SUMMARY: The past decade has seen advancement in costimulatory blockade, as well as immune modulatory therapy with monoclonal antibodies. Cellular therapies such as CAR-Tregs remain in the early clinical trial phase.
RECENT FINDINGS: Co-stimulation blockade has been explored as both tolerogenic and maintenance immunosuppression over the last two decades, resulting in the application of belatacept in clinical settings. Dual co-stimulation blockade is the latest in this area of study. Recent updates in monoclonal antibody-based immunotherapy have resulted in widespread off-label clinical implementation of eculizumab and alemtuzumab with new drugs still in phase II/II trials. Additional strategies, including autologous regulatory T cell (Treg) and chimeric antigen receptor-Treg cell (CAR-Treg) based therapies, are at the forefront of therapeutic immunomodulation. Early data have demonstrated safety and feasibility with ongoing phase II studies in these cell-based therapies, aiming to verify efficacy in early and long-term graft survival.
SUMMARY: The past decade has seen advancement in costimulatory blockade, as well as immune modulatory therapy with monoclonal antibodies. Cellular therapies such as CAR-Tregs remain in the early clinical trial phase.